The latanoprost monotherapy survey in New Zealand, 2000.
AI Summary
New Zealand ophthalmologists studied latanoprost monotherapy, finding 85% of patients achieved adequate eye pressure control. This suggests latanoprost is effective as a first-line treatment for many.
Abstract
Background
A State subsidy for latanoprost has been recently introduced. It is subject to several conditions including that it should only be used as monotherapy.
Method
A prospective survey of all New Zealand ophthalmologists was undertaken to determine the outcome of the widespread trial of latanoprost monotherapy. The return rate was 82%.
Results
Of 2900 patients on latanoprost nation-wide, 14.7% were monotherapy failures. Of these, 93% were due to inadequate intraocular pressure control but this subgroup had adequate control on two or more medications in 88%. Ophthalmologists had 635 patients that were not trialed as monotherapy, of which 565 (89%) were due to a perceived risk.
Conclusions
In those patients treated with latanoprost, 85% were adequately controlled as monotherapy.
MeSH Terms
Shields Classification
Related Articles5
Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
Observational StudyMeasurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
Cohort StudyDiscrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins.
Observational StudyLatanoprost exposure in pregnancy.
Observational StudyIridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.